

DAFTAR PUSTAKA

Abbas, A.K., Lichtman, A.H., Pillai, S., 2017. Cellular and Molecular Immunology. Elsevier Health Sciences.

Akiba, J., Yano, H., Ogasawara, S., Higaki, K., Kojiro, M., 2001. Expression and function of interleukin-8 in human hepatocellular carcinoma. International Journal of Oncology. <https://doi.org/10.3892/ijo.18.2.257>

Alkhoury, N., Harrison, S.A., 2023. Need-to-Know NAFLD: The Complete Guide to Nonalcoholic Fatty Liver Disease. CRC Press.

Alves-Bezerra, M., Cohen, D.E., 2017. Triglyceride Metabolism in the Liver. Comprehensive Physiology 8, 1–8. <https://doi.org/10.1002/cphy.c170012>

Arab, J.P., Arrese, M., Trauner, M., 2018. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease 13, 321–350. <https://doi.org/10.1146/annurev-pathol-020117-043617>

Basaranoglu, M., Neuschwander-Tetri, B.A., 2006. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterology & hepatology 2, 282–291.

Berberich, A.J., Hegele, R.A., 2021. A Modern Approach to Dyslipidemia. Endocrine Reviews 43, 611–653. <https://doi.org/10.1210/endrev/bnab037>

Birerdinc, A., Keaton, M., Doyle, K., Younoszai, Z., Wang, L., Goodman, Z., Baranova, A., Younossi, Z., 2014. IL-8 Is an Important Contributor to Both the Progression of Systematic Inflammation and Increasing Severity of Non-Alcoholic Fatty Liver Disease (NAFLD). American Journal of Gastroenterology 109, S168. <https://doi.org/10.14309/00000434-201410002-00575>

Buzzetti, E., Pinzani, M., Tsochatzis, E.A., 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038–1048. <https://doi.org/10.1016/j.metabol.2015.12.012>

Campana, L., Esser, H., Huch, M., Forbes, S., 2021. Liver regeneration and inflammation: from fundamental science to clinical applications. Nature Reviews Molecular Cell Biology 22, 608–624. <https://doi.org/10.1038/s41580-021-00373-7>

Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., Harrison, S.A., Brunt, E.M., Sanyal, A.J., 2017. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357. <https://doi.org/10.1002/hep.29367>

Coort, S.L.M., Willems, J., Coumans, W.A., van der Vusse, G.J., Bonen, A., Glatz, J.F.C., Luiken, J.J.F.P., 2002. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake, in: Cellular Lipid Binding Proteins. Springer US, Boston, MA, pp. 213–219.

CXCL8 [WWW Document], 2023. . NCBI. URL <https://www.ncbi.nlm.nih.gov/gene/3576> (accessed 12.17.23).

Day, C.P., James, O.F.W., 1998. Steatohepatitis: A tale of two “hits”? Gastroenterology 114, 842–845. [https://doi.org/10.1016/s0016-5085\(98\)70599-2](https://doi.org/10.1016/s0016-5085(98)70599-2)

Dobri, A.-M., Codrici, E., Popescu, I.-D., Albuлесcu, L., Fertig, E.T., Enciu, A.-M., Tanase, C., Hinescu, M.E., 2022. Low-Concentrations of Fatty Acids Induce an Early Increase in IL-8 Levels in Normal Human Astrocytes. Metabolites 12, 329. <https://doi.org/10.3390/metabo12040329>

Dowman, J.K., Tomlinson, J.W., Newsome, P.N., 2009. Pathogenesis of non-alcoholic fatty liver disease. QJM 103, 71–83. <https://doi.org/10.1093/qjmed/hcp158>

Feng, Y., Sun, W., Sun, F., Yin, G., Liang, P., Chen, S., Liu, X., Jiang, T., Zhang, F., 2022. Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver. Drug Design, Development and Therapy Volume 16, 3829–3845. <https://doi.org/10.2147/dddt.s386982>

Glass, O., Henao, R., Patel, K., Guy, C.D., Gruss, H.J., Syn, W.-K., Moylan, C.A., Streilein, R., Hall, R., Diehl, A.M., Abdelmalek, M.F., 2018. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications 2, 1344–1355. <https://doi.org/10.1002/hep4.1237>

Glatz, JanF.C., Luiken, JoostJ.F.P., 2018. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. Journal of Lipid Research 59, 1084–1093. <https://doi.org/10.1194/jlr.r082933>

Guo, X., Yin, X., Liu, Z., Wang, J., 2022. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. International Journal of Molecular Sciences 23, 15489. <https://doi.org/10.3390/ijms232415489>

Gurr, M.I., Harwood, J.L., Frayn, K.N., Murphy, D.J., Michell, R.H., 2016. Lipids: Biochemistry, Biotechnology and Health. John Wiley & Sons.

Hamilton, J.A., 2007. New insights into the roles of proteins and lipids in membrane

transport of fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids 77, 355–361. <https://doi.org/10.1016/j.plefa.2007.10.020>

Hao, J.-W., Wang, J., Guo, H., Zhao, Y.-Y., Sun, H.-H., Li, Y.-F., Lai, X.-Y., Zhao, N., Wang, X., Xie, C., Hong, L., Huang, X., Wang, H.-R., Li, C.-B., Liang, B., Chen, S., Zhao, T.-J., 2020. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nature Communications 11. <https://doi.org/10.1038/s41467-020-18565-8>

Hasan, A., Akhter, N., Al-Roub, A., Thomas, R., Kochumon, S., Wilson, A., Koshy, M., Al-Ozairi, E., Al-Mulla, F., Ahmad, R., 2019. TNF- α in Combination with Palmitate Enhances IL-8 Production via The MyD88- Independent TLR4 Signaling Pathway: Potential Relevance to Metabolic Inflammation. International Journal of Molecular Sciences 20, 4112. <https://doi.org/10.3390/ijms20174112>

Huh, Y., Cho, Y.J., Nam, G.E., 2022. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. Journal of obesity & metabolic syndrome 31, 17–27. <https://doi.org/10.7570/jomes22021>

Joshi-Barve, S., Barve, S.S., Amancherla, K., Gobejishvili, L., Hill, D., Cave, M., Hote, P., McClain, C.J., 2007. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46, 823–830. <https://doi.org/10.1002/hep.21752>

Jou, J., Choi, S., Diehl, A., 2008. Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease 28, 370–379. <https://doi.org/10.1055/s-0028-1091981>

Karunakaran, U., Elumalai, S., Moon, J.-S., Won, K.-C., 2021. CD36 Signal Transduction in Metabolic Diseases: Novel Insights and Therapeutic Targeting. Cells 10, 1833. <https://doi.org/10.3390/cells10071833>

Kementerian Kesehatan Republik Indonesia, 2018. Hasil Utama Riskesdas 2018. Lembaga Penerbitan Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.

Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.-C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J., 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321. <https://doi.org/10.1002/hep.20701>

Koyama, Y., Brenner, D.A., 2017. Liver inflammation and fibrosis. Journal of Clinical Investigation 127, 55–64. <https://doi.org/10.1172/jci88881>

Krisanits, B., Randise, J.F., Burton, C.E., Findlay, V.J., Turner, D.P., 2020. Pubertal

mammary development as a “susceptibility window” for breast cancer disparity, in: *Advances in Cancer Research*. Elsevier, pp. 57–82.

Kuda, O., Pietka, T.A., Demianova, Z., Kudova, E., Cvacka, J., Kopecky, J., Abumrad, N.A., 2013. Sulfo-N-succinimidyl Oleate (SSO) Inhibits Fatty Acid Uptake and Signaling for Intracellular Calcium via Binding CD36 Lysine 164. *Journal of Biological Chemistry* 288, 15547–15555. <https://doi.org/10.1074/jbc.m113.473298>

Larsson, P., Engqvist, H., Biermann, J., Werner Rönnerman, E., Forssell-Aronsson, E., Kovács, A., Karlsson, P., Helou, K. and Parris, T.Z. (2020). Optimization of Cell Viability Assays to Improve Replicability and Reproducibility of Cancer Drug Sensitivity Screens. *Scientific Reports*, 10(1), p.5798. doi:<https://doi.org/10.1038/s41598-020-62848-5>

Ma, Q., Wen, L., Tian, Y., Ma, L., Wen, Z., Kun, Y., Xu, M., Liu, X., 2023. Sulfosuccinimidyl oleate ameliorates the high-fat diet-induced obesity syndrome by reducing intestinal and hepatic absorption. *Frontiers in Pharmacology* 14. <https://doi.org/10.3389/fphar.2023.1193006>

Ohgami, N., Nagai, R., Ikemoto, M., Arai, H., Miyazaki, A., Hakamata, H., Horiuchi, S., Nakayama, H., 2002. CD36, serves as a receptor for advanced glycation endproducts (AGE). *Journal of Diabetes and its Complications* 16, 56–59. [https://doi.org/10.1016/s1056-8727\(01\)00208-2](https://doi.org/10.1016/s1056-8727(01)00208-2)

Pepino, M.Y., Kuda, O., Samovski, D., Abumrad, N.A., 2014. Structure-Function of CD36 and Importance of Fatty Acid Signal Transduction in Fat Metabolism. *Annual Review of Nutrition* 34, 281–303. <https://doi.org/10.1146/annurev-nutr-071812-161220>

Petersen, M.C., Shulman, G.I., 2018. Mechanisms of Insulin Action and Insulin Resistance. *Physiological Reviews* 98, 2133–2223. <https://doi.org/10.1152/physrev.00063.2017>

PubChem, n.d. Sulfosuccinimidyl Oleate Sodium [WWW Document]. PubChem. URL <https://pubchem.ncbi.nlm.nih.gov/compound/90469841> (accessed 12.3.23). Rada, P., González-Rodríguez, Á., García-Monzón, C., Valverde, Á.M., 2020. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? *Cell death & disease* 11, 802. <https://doi.org/10.1038/s41419-020-03003-w>

Robinson, M.W., Harmon, C., O’Farrelly, C., 2016. Liver immunology and its role in inflammation and homeostasis. *Cellular & Molecular Immunology* 13, 267–276. <https://doi.org/10.1038/cmi.2016.3>

Satapathy, S.K., Bernstein, D.E., Roth, N.C., 2022. Liver transplantation in patients with non-alcoholic steatohepatitis and alcohol-related liver disease: the dust is yet

to settle. *Translational Gastroenterology and Hepatology* 7, 23–23.
<https://doi.org/10.21037/tgh-2020-15>

Sazonova, E.V., Chesnokov, M.S., Zhivotovsky, B. and Kopeina, G.S. (2022). Drug Toxicity assessment: Cell Proliferation versus Cell Death. *Cell Death Discovery*, 8(1). doi:<https://doi.org/10.1038/s41420-022-01207-x>

Sebaugh, J.L. (2011). Guidelines for Accurate EC50/IC50 Estimation. *Pharmaceutical Statistics*, 10(2), pp.128–34. doi:<https://doi.org/10.1002/pst.426>.
Seki, E., Schwabe, R.F., 2015. Hepatic inflammation and fibrosis: Functional links and key pathways. *Hepatology* 61, 1066–1079. <https://doi.org/10.1002/hep.27332>

Silverstein, R.L., Li, W., Park, Y.M., Rahaman, S.O., 2010. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. *Transactions of the American Clinical and Climatological Association* 121, 206–20.

Simon, T.G., Roelstraete, B., Khalili, H., Hagström, H., Ludvigsson, J.F., 2021. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. *Gut* 70, 1375–1382. <https://doi.org/10.1136/gutjnl-2020-322786>

Siswanto, S., 2014. *Buku Studi Diet Total: Survei Konsumsi Makanan Individu Indonesia 2014*. Lembaga Penerbitan Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.

Song, Z., Xiaoli, A.M., Yang, F., 2018. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. *Nutrients* 10. <https://doi.org/10.3390/nu10101383>

Soresi, M., Cabibi, D., Giglio, R.V., Martorana, S., Guercio, G., Porcasi, R., Terranova, A., Lazzaro, L.A., Emma, M.R., Augello, G., Cervello, M., Pantuso, G., Montalto, G., Giannitrapani, L., 2020. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. *BioMed Research International* 2020, 1–7. <https://doi.org/10.1155/2020/5023157>

Taskinen, M.-R., Borén, J., 2015. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. *Atherosclerosis* 239, 483–495. <https://doi.org/10.1016/j.atherosclerosis.2015.01.039>

Thorne, R.F. et al. (2010) ‘Palmitoylation of CD36/fat regulates the rate of its post-transcriptional processing in the endoplasmic reticulum’, *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1803(11), pp. 1298–1307. <https://doi.org/10.1016/j.bbamcr.2010.07.002>.

Trovato, F.M., Catalano, D., Musumeci, G., Trovato, G.M., 2014. 4Ps medicine of

the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA Journal 5. <https://doi.org/10.1186/1878-5085-5-21>

Tsuzuki, S., Kimoto, Y., Yamasaki, M., Sugawara, T., Manabe, Y., Inoue, K., Sasaki, T., 2021. Assessment of direct binding interaction between CD36 and its potential lipid ligands using a peptide mimic of the receptor labeled with a fluorophore. Biomedical Research 42, 181–191. <https://doi.org/10.2220/biomedres.42.181>

Urso, C.J., Zhou, H., 2021. Role of CD36 in Palmitic Acid Lipotoxicity in Neuro-2a Neuroblastoma Cells. Biomolecules 11, 1567. <https://doi.org/10.3390/biom11111567>

Wasityastuti, W., Nugrahaningsih, D.A., Tsany, S.F., Pasaribu, H.S., Saffana, R.D., 2023. *Knockdown* Reseptor *Scavenger* dan Translokator Asam Lemak (CD36): Pemodelan Modulasi Metabolik *In Vitro* untuk Kajian Patofisiologi dan Anti-Inflamasi/Imunoproteksi. Proposal Penelitian. Universitas Gadjah Mada.

Wilson, C.G., Tran, J.L., Erion, D.M., Vera, N.B., Febbraio, M., Weiss, E.J., 2015. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. Endocrinology 157, 570–585. <https://doi.org/10.1210/en.2015-1866>

Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., 2016. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84. <https://doi.org/10.1002/hep.28431>

Zhao, L., Li, Yuqi, Ding, Q., Li, Yanping, Chen, Y., Ruan, X.Z., 2021. CD36 Senses Dietary Lipids and Regulates Lipids Homeostasis in the Intestine. Frontiers in Physiology 12. <https://doi.org/10.3389/fphys.2021.669279>

Zhao, L., Zhang, C., Luo, X., Wang, P., Zhou, W., Zhong, S., Xie, Y., Jiang, Y., Yang, P., Tang, R., Pan, Q., Hall, A.R., Luong, T.V., Fan, J., Varghese, Z., Moorhead, J.F., Pinzani, M., Chen, Y., Ruan, X.Z., 2018. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. Journal of Hepatology 69, 705–717. <https://doi.org/10.1016/j.jhep.2018.04.006>